346 related articles for article (PubMed ID: 24671867)
1. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment.
Rizzo MR; Barbieri M; Boccardi V; Angellotti E; Marfella R; Paolisso G
J Gerontol A Biol Sci Med Sci; 2014 Sep; 69(9):1122-31. PubMed ID: 24671867
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of a DPP-4 inhibitor as assessed by continuous glucose monitoring (CGM)].
Mori Y
Nihon Rinsho; 2011 May; 69(5):912-7. PubMed ID: 21595281
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus.
Meng J; Yan R; Zhang C; Bai X; Yang X; Yang Y; Feng T; Liu X
Lipids Health Dis; 2023 Dec; 22(1):219. PubMed ID: 38082288
[TBL] [Abstract][Full Text] [Related]
4. Dose adjustment of metformin and dipeptidyl-peptidase IV inhibitors in diabetic patients with renal dysfunction.
Melzer-Cohen C; Karasik A; Leuschner PJ; Azuri J; Shalev V; Chodick G
Curr Med Res Opin; 2018 Oct; 34(10):1849-1854. PubMed ID: 29611727
[TBL] [Abstract][Full Text] [Related]
5. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
Goldenberg RM
Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
[TBL] [Abstract][Full Text] [Related]
6. Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38).
Kanatsuka A; Sato Y; Kawai K; Hirao K; Kobayashi M; Kashiwagi A; ; Abe N; Arai K; Fujiya H; Fukumoto Y; Dake F; Iizumi T; Ito M; Iwasaki K; Kanamori A; Kato S; Kato M; Kawara A; Kimura K; Chikamori K; Iemitsu K; Kou S; Kudo M; Kurihara Y; Lee G; Tsuruoka A; Manda N; Matoba K; Hayashi H; Minami M; Kuribayashi N; Miyazawa K; Chiba Y; Osonoi T; Nakamura S; Sasaki H; Komori K; Oishi M; Okada A; Okuguchi F; Yanagisawa M; Sugimoto H; Sugiyama H; Takai M; Takaki M; Takamura H; Takeda H; Takeda H; Tanaka K; Miwa T; Tomonaga O; Taguchi M; Yamazaki K; Wada T; Yagi N; Yamaoka K; Yuhara A
J Diabetes Investig; 2016 May; 7(3):386-95. PubMed ID: 27330726
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
8. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
Fadini GP; Avogaro A; Degli Esposti L; Russo P; Saragoni S; Buda S; Rosano G; Pecorelli S; Pani L;
Eur Heart J; 2015 Sep; 36(36):2454-62. PubMed ID: 26112890
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
[TBL] [Abstract][Full Text] [Related]
10. The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring.
Yata Y; Hosojima M; Kabasawa H; Ishikawa T; Kaseda R; Iino N; Suzuki Y; Saito A; Narita I
Intern Med; 2017 Oct; 56(19):2555-2562. PubMed ID: 28883231
[TBL] [Abstract][Full Text] [Related]
11. Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment.
Borzì AM; Condorelli G; Biondi A; Basile F; Vicari ESD; Buscemi C; Luca S; Vacante M
Arch Gerontol Geriatr; 2019; 84():103896. PubMed ID: 31204117
[TBL] [Abstract][Full Text] [Related]
12. Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment.
Jeong SH; Kim HR; Kim J; Kim H; Hong N; Jung JH; Baik K; Cho H; Lyoo CH; Ye BS; Sohn YH; Seong JK; Lee PH
Neurology; 2021 Sep; 97(11):e1110-e1122. PubMed ID: 34380754
[TBL] [Abstract][Full Text] [Related]
13. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study.
Baksh S; Wen J; Mansour O; Chang HY; McAdams-DeMarco M; Segal JB; Ehrhardt S; Alexander GC
Sci Rep; 2021 Aug; 11(1):16637. PubMed ID: 34404825
[TBL] [Abstract][Full Text] [Related]
16. Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues.
Battini V; Barbieri MA; Carnovale C; Spina E; Clementi E; Sessa M
J Neurol; 2024 Jun; 271(6):3417-3425. PubMed ID: 38517522
[TBL] [Abstract][Full Text] [Related]
17. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice.
Bazo-Alvarez JC; Pal K; Pham TM; Nazareth I; Petersen I; Sharma M
Sci Rep; 2021 Dec; 11(1):23826. PubMed ID: 34903733
[TBL] [Abstract][Full Text] [Related]
19. The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia.
Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
Alzheimers Res Ther; 2021 Dec; 13(1):197. PubMed ID: 34857046
[TBL] [Abstract][Full Text] [Related]
20. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]